Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Non-Current Assets (2018 - 2025)

10x Genomics (TXG) has disclosed Other Non-Current Assets for 8 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 29.45% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 29.45% year-over-year, with the annual reading at $2.9 million for FY2025, 29.45% down from the prior year.
  • Other Non-Current Assets hit $2.9 million in Q4 2025 for 10x Genomics, up from $201000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $61.0 million in Q4 2023 to a low of $201000.0 in Q3 2025.
  • Historically, Other Non-Current Assets has averaged $12.1 million across 5 years, with a median of $4.9 million in 2024.
  • Biggest five-year swings in Other Non-Current Assets: soared 539.61% in 2023 and later plummeted 95.9% in 2025.
  • Year by year, Other Non-Current Assets stood at $8.6 million in 2021, then tumbled by 66.37% to $2.9 million in 2022, then skyrocketed by 2002.03% to $61.0 million in 2023, then tumbled by 93.23% to $4.1 million in 2024, then fell by 29.45% to $2.9 million in 2025.
  • Business Quant data shows Other Non-Current Assets for TXG at $2.9 million in Q4 2025, $201000.0 in Q3 2025, and $2.7 million in Q2 2025.